Analyze Diet
Annals of the New York Academy of Sciences1999; 878; 675-677; doi: 10.1111/j.1749-6632.1999.tb07759.x

MMP inhibition by chemically modified tetracycline-3 (CMT-3) in equine pulmonary epithelial lining fluid.

Abstract: No abstract available
Publication Date: 1999-07-23 PubMed ID: 10415805DOI: 10.1111/j.1749-6632.1999.tb07759.xGoogle Scholar: Lookup
The Equine Research Bank provides access to a large database of publicly available scientific literature. Inclusion in the Research Bank does not imply endorsement of study methods or findings by Mad Barn.
  • Journal Article

Cite This Article

APA
Maisi P, Kiili M, Raulo SM, Pirilä E, Sorsa T. (1999). MMP inhibition by chemically modified tetracycline-3 (CMT-3) in equine pulmonary epithelial lining fluid. Ann N Y Acad Sci, 878, 675-677. https://doi.org/10.1111/j.1749-6632.1999.tb07759.x

Publication

ISSN: 0077-8923
NlmUniqueID: 7506858
Country: United States
Language: English
Volume: 878
Pages: 675-677

Researcher Affiliations

Maisi, P
  • Department of Clinical Veterinary Sciences, Faculty of Veterinary Medicine, University of Helsinki, Finland. paivi.maisi@helsinki.fi
Kiili, M
    Raulo, S M
      Pirilä, E
        Sorsa, T

          MeSH Terms

          • Animals
          • Body Fluids / enzymology
          • Epithelial Cells / cytology
          • Epithelial Cells / enzymology
          • Gelatin / metabolism
          • Horses
          • Humans
          • Kinetics
          • Matrix Metalloproteinase 9
          • Matrix Metalloproteinase Inhibitors
          • Metalloendopeptidases / antagonists & inhibitors
          • Protease Inhibitors / pharmacology
          • Recombinant Proteins / antagonists & inhibitors
          • Tetracyclines / pharmacology
          • Trachea / cytology
          • Trachea / enzymology

          Citations

          This article has been cited 5 times.
          1. Garrido-Mesa J, Adams K, Galvez J, Garrido-Mesa N. Repurposing tetracyclines for acute respiratory distress syndrome (ARDS) and severe COVID-19: a critical discussion of recent publications.. Expert Opin Investig Drugs 2022 May;31(5):475-482.
            doi: 10.1080/13543784.2022.2054325pubmed: 35294307google scholar: lookup
          2. Zarogoulidis P, Papanas N, Kioumis I, Chatzaki E, Maltezos E, Zarogoulidis K. Macrolides: from in vitro anti-inflammatory and immunomodulatory properties to clinical practice in respiratory diseases.. Eur J Clin Pharmacol 2012 May;68(5):479-503.
            doi: 10.1007/s00228-011-1161-xpubmed: 22105373google scholar: lookup
          3. Li J, Zhou S, Huynh H, Duan W, Chan E. Alteration of the pharmacokinetics of COL-3, a matrix metalloproteinase inhibitor, due to acute gastrointestinal toxicity of doxorubicin.. Pharm Res 2005 Nov;22(11):1954-63.
            doi: 10.1007/s11095-005-6096-4pubmed: 16086226google scholar: lookup
          4. Li J, Zhou S, Huynh H, Chan E. Significant intestinal excretion, one source of variability in pharmacokinetics of COL-3, a chemically modified tetracycline.. Pharm Res 2005 Mar;22(3):397-404.
            doi: 10.1007/s11095-004-1877-8pubmed: 15835745google scholar: lookup
          5. Tolomeo M, Grimaudo S, Milano S, La Rosa M, Ferlazzo V, Di Bella G, Barbera C, Simoni D, D'Agostino P, Cillari E. Effects of chemically modified tetracyclines (CMTs) in sensitive, multidrug resistant and apoptosis resistant leukaemia cell lines.. Br J Pharmacol 2001 May;133(2):306-14.
            doi: 10.1038/sj.bjp.0704068pubmed: 11350867google scholar: lookup